Natus Medical Inc

Find Ratings Reports
BABY : NASDAQ : Health Care
$34.35 up 0.6 | 1.78%
Today's Range: 33.75 - 34.55
Avg. Daily Volume: 320300.0
05/24/17 - 4:00 PM ET

Financial Analysis


NATUS MEDICAL INC's gross profit margin for the first quarter of its fiscal year 2017 has decreased when compared to the same period a year ago. Even though sales increased, the net income has decreased, representing a decrease to the bottom line. NATUS MEDICAL INC is extremely liquid. Currently, the Quick Ratio is 2.66 which clearly shows the ability to cover any short-term cash needs. The company's liquidity has increased from the same period last year.

During the same period, stockholders' equity ("net worth") has increased by 7.15% from the same quarter last year. Overall, the key liquidity measurements indicate that the company is very unlikely to face financial difficulties in the near future.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. To learn more visit www.TheStreetRatings.com.



Income Statement Q1 FY17 Q1 FY16
Net Sales ($mil)124.6687.33
EBITDA ($mil)15.3815.74
EBIT ($mil)8.6311.51
Net Income ($mil)0.358.54


Balance Sheet Q1 FY17 Q1 FY16
Cash & Equiv. ($mil)112.8681.29
Total Assets ($mil)688.86472.73
Total Debt ($mil)149.890.0
Equity ($mil)420.41392.35


Profitability Q1 FY17 Q1 FY16
Gross Profit Margin59.0964.83
EBITDA Margin12.3318.01
Operating Margin6.9313.18
Sales Turnover0.610.79
Return on Assets4.998.0
Return on Equity8.189.65
Debt Q1 FY17 Q1 FY16
Current Ratio3.73.37
Debt/Capital0.260.0
Interest Expense0.00.03
Interest Coverage0.0371.39


Share Data Q1 FY17 Q1 FY16
Shares outstanding (mil)32.9233.09
Div / share0.00.0
EPS0.010.26
Book value / share12.7711.86
Institutional Own % n/a n/a
Avg Daily Volume321414.0549638.0

Valuation


HOLD. The current P/E ratio indicates a discount compared to an average of 41.69 for the Health Care Equipment & Supplies industry and a premium compared to the S&P 500 average of 25.02. To use another comparison, its price-to-book ratio of 2.65 indicates a discount versus the S&P 500 average of 3.00 and a significant discount versus the industry average of 4.72. The price-to-sales ratio is well above the S&P 500 average, but well below the industry average. Upon assessment of these and other key valuation criteria, NATUS MEDICAL INC proves to trade at a discount to investment alternatives within the industry.


Price/Earnings
1 2 3 4 5
premium   discount
  Price/Cash Flow
1 2 3 4 5
premium   discount
BABY 32.60 Peers 41.69   BABY 19.97 Peers 23.09

Discount. A lower P/E ratio than its peers can signify a less expensive stock or lower growth expectations.

BABY is trading at a discount to its peers.

 

Discount. The P/CF ratio, a stock’s price divided by the company's cash flow from operations, is useful for comparing companies with different capital requirements or financing structures.

BABY is trading at a discount to its peers.

 
Price/Projected
Earnings
1 2 3 4 5
premium   discount
  Price to
Earnings/Growth
1 2 3 4 5
premium   discount
BABY 16.62 Peers 23.68   BABY 1.03 Peers 0.90

Discount. A lower price-to-projected earnings ratio than its peers can signify a less expensive stock or lower future growth expectations.

BABY is trading at a discount to its peers.

 

Premium. The PEG ratio is the stock’s P/E divided by the consensus estimate of long-term earnings growth. Faster growth can justify higher price multiples.

BABY trades at a premium to its peers.

 
Price/Book
1 2 3 4 5
premium   discount
  Earnings Growth
1 2 3 4 5
lower   higher
BABY 2.65 Peers 4.72   BABY -9.57 Peers 126.02

Discount. A lower price-to-book ratio makes a stock more attractive to investors seeking stocks with lower market values per dollar of equity on the balance sheet.

BABY is trading at a significant discount to its peers.

 

Lower. Elevated earnings growth rates can lead to capital appreciation and justify higher price-to-earnings ratios.

However, BABY is expected to significantly trail its peers on the basis of its earnings growth rate.

 
Price/Sales
1 2 3 4 5
premium   discount
  Sales Growth
1 2 3 4 5
premium   discount
BABY 2.66 Peers 4.96   BABY 12.15 Peers 14.58

Discount. In the absence of P/E and P/B multiples, the price-to-sales ratio can display the value investors are placing on each dollar of sales.

BABY is trading at a significant discount to its industry on this measurement.

 

Lower. A sales growth rate that trails the industry implies that a company is losing market share.

BABY trails its peers on the basis of sales growth

 

 

Latest Stock Upgrades/Downgrades